New hope for leukemia patients: major trial tests targeted drug
NCT ID NCT07223814
Summary
This study is testing if adding a new drug called bleximenib to standard chemotherapy works better than chemotherapy alone for adults newly diagnosed with specific genetic types of acute myeloid leukemia (AML). About 875 participants will receive standard chemo plus either bleximenib or a placebo (inactive pill), and neither they nor their doctors will know which one they get. The main goal is to see if the combination helps patients live longer without their cancer returning.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.